Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11541996 | 0.85 | HTR2C (0.40) | HTR2AHTR2CALDH1A1CYP2A13LMNA | |
| SCHEMBL3214592 | 0.80 | KDM1A (0.36) | HTR2AHTR2CALDH1A1CYP2A13LMNA | |
| SCHEMBL7390254 | 0.76 | L3MBTL1 (0.45) | ALDH1A1SMN1; SMN2 | |
| Phosphine SCHEMBL9482786 | 0.74 | L3MBTL1 (0.44) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11543429 | 0.71 | MAPT (0.41) | — | |
| SCHEMBL9531677 | 0.70 | MAPK1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3203338 | 0.69 | HTR2A (0.35) | HTR2AHTR2CALDH1A1CYP2A13LMNA | |
| SCHEMBL1168000 | 0.67 | ALDH1A1 (0.37) | HTR2AHTR2CALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL11545255 | 0.66 | ALDH1A1 (0.34) | ALDH1A1CYP2A13LMNASMN1; SMN2 | |
| SCHEMBL4783521 | 0.66 | L3MBTL1 (0.43) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235550-B2 | Polycyclic azaindole compounds | LES LABORATOIRES SERVIER (FR) | 2007-06-26 | — | — | US | disclosed |
| US-6667304-B2 | Affinity for melatonin receptors; sleep disorders; N-(2-(2-methoxy-6H-pyrido(2',3':4,5)pyrrolo(2,1-a)isoindol-11 -yl)ethyl)acetamide; N-(2-(3-methoxy-6,7,8,9-tetrahydropyrido (3,2-b)indolizin-5-yl) ethyl)acetamide | LES LABORATOIRES SERVIER (FR) | 2003-12-23 | — | — | US | disclosed |
| US-20030134847-A1 | New polycyclic azaindole compounds | GUILLAUMET GERALD (FR) | 2003-07-17 | — | — | US | disclosed |
| US-20030105087-A1 | For therapy of melatoninergic disorders | GUILLAUMET GERALD (FR) | 2003-06-05 | — | — | US | disclosed |
| EP-1092717-B1 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| US-6495543-B1 | TREATING OR PREVENTING MELATONINERGIC DISORDERS | LES LABORATOIRES SERVIER (FR) | 2002-12-17 | — | — | US | disclosed |
| EP-1092717-A2 | Polycyclic azaindole derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134847-A1 | New polycyclic azaindole compounds | AZI2, DRD3, CCNI | HTR2A 134/4885HTR2C 23/4885ALDH1A1 196/4885 |
| US-20030105087-A1 | For therapy of melatoninergic disorders | MTNR1A, MTNR1B, TPH1 | HTR2A 29/4885HTR2C 20/4885ALDH1A1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.